PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

NCT ID: NCT00679835

Last Updated: 2019-11-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-06-03
• Study Completion Date: 2008-11-20

Brief Summary

This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 2 to 6 years who have infections that are caused by a specific group of bacteria (called Gram-positive bacteria).

Conditions

Gram Positive Infection; Concurrent Antibiotic Treatment

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Group 1

8 mg/kg over a one hour infusion

Group Type: EXPERIMENTAL

daptomycin

Intervention Type: DRUG

i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.

Group 2

10mg/kg over a one or two hour infusion

Group Type: EXPERIMENTAL

daptomycin

Intervention Type: DRUG

i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.

Interventions

daptomycin

i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.

Intervention Type: DRUG

Other Intervention Names

Cubicin

Eligibility Criteria

Inclusion Criteria

• Written parental (or appropriate legal representative) informed consent prior to any study-related procedure not part of normal medical care;
• Male or female between the ages of 2 and 6 years old, inclusive;
• Able to comply with the protocol for the duration of the study;
• Clinically stable with no evidence of hemodynamic instability (defined as a requirement for pharmacological intervention to manage blood pressure) in the 72 hour window prior to enrollment, and no history or evidence of renal or hepatic compromise;
• Suspected or diagnosed Gram-positive infection for which the subject is receiving standard antibiotic therapy;
• A calculated creatinine clearance rate (CLcr) ≥ 80 ml/min/1.73m2 as determined by the Schwartz equation at baseline;
• Creatine phosphokinase (CPK) levels less than 2X ULN (upper limit of normal) at baseline.
• Presence of two patent intravenous lines (or comparable means of venous access) prior to dosing on Study Day 1.

Exclusion Criteria

• Investigational drug use (including daptomycin) or participation in any experimental procedure in the 30 days preceding study entry;
• Known allergy/ hypersensitivity to daptomycin;
• History of clinically significant cardiovascular, renal, hepatic, pulmonary (well-controlled asthma is acceptable), gastrointestinal, endocrine, hematologic, autoimmune disease or primary immune deficiency;
• Pneumonia as sole Gram-positive infection being treated with standard antibiotics;
• Subjects with clinically significant abnormal laboratory test results [including electrocardiograms (ECGs)], as determined by Investigator;
• Administration of rifampin within 7 days of study drug administration;
• Body mass index (BMI) that is outside of the 5th to 95th percentile;
• Subjects in whom collection of the required blood volume would put them at risk of hemodynamic disturbance (at the discretion of Investigator);
• History of or current clinically significant (at the discretion of the Investigator) muscular disease, nervous system or seizure disorder;
• Administration of intramuscular injection between baseline and study drug administration or expected intramuscular injection within 24 hours following dosing;
• Expected surgical procedure(s) within 24 hours prior to and following dosing;
• Unexplained muscular weakness, history of peripheral neuropathy, Guillian-Barre or spinal cord injury;
• History of or current rhabdomyolysis.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 6 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Children's Mercy Hospital

Kansas City, Missouri, United States

Countries

United States

References

Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J, Benziger DP. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2011 Aug;30(8):712-4. doi: 10.1097/INF.0b013e31820fc8e1.

Reference Type: RESULT

PMID: 21317681 (View on PubMed)

Other Identifiers

DAP-PEDS-07-02

Identifier Type: OTHER

Identifier Source: secondary_id

3009-023

Identifier Type: -

Identifier Source: org_study_id